PRESS RELEASE published on 02/21/2026 at 12:00, 8 months 14 days ago Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 Abivax presents first evidence of anti-fibrotic activity for Obefazimod and new clinical efficacy and safety analyses in inflammatory bowel disease at ECCO 2026 Abivax Obefazimod Clinical Efficacy Inflammatory Bowel Disease Anti-fibrotic
BRIEF published on 01/26/2026 at 18:05, 9 months 11 days ago ABIVAX: Share capital and voting rights as of December 31, 2025 Voting Rights Biotechnology Actions AMF Abivax
BRIEF published on 01/26/2026 at 18:05, 9 months 11 days ago ABIVAX : Composition du capital social et droits de vote au 31 décembre 2025 Droits De Vote Biotechnologie Actions AMF Abivax
PRESS RELEASE published on 01/26/2026 at 18:00, 9 months 12 days ago ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 31.12.25. ABIVAX annonce le nombre d'actions et de droits de vote au 31.12.25. Société de biotechnologie axée sur les traitements thérapeutiques dans les maladies inflammatoires chroniques Droits De Vote Biotechnologie Actions Abivax Maladies Inflammatoires
BRIEF published on 01/07/2026 at 22:10, 9 months 30 days ago Abivax unveils its objectives for 2026 Abivax Obefazimod Phase 3 2026 RCH
BRIEF published on 01/07/2026 at 22:10, 9 months 30 days ago Abivax dévoile ses objectifs pour 2026 Abivax Obefazimod Phase 3 2026 RCH
BRIEF published on 01/07/2026 at 22:10, 9 months 30 days ago Abivax Reveals Strategic Plans for 2026 Regulatory Filing Abivax 2026 Outlook Ulcerative Colitis Market Obefazimod Trials Crohn’s Disease Research
BRIEF published on 01/07/2026 at 22:10, 9 months 30 days ago Abivax dévoile ses plans stratégiques pour 2026 Dépôt Réglementaire Perspectives D'Abivax Pour 2026 Marché De La Colite Ulcéreuse Essais Cliniques Sur L'obefazimod Recherche Sur La Maladie De Crohn
PRESS RELEASE published on 01/07/2026 at 22:05, 9 months 30 days ago Abivax présente ses perspectives pour 2026 Abivax présente ses perspectives pour 2026, annonçant des nouveautés dans le traitement de la rectocolite hémorragique, les progrès des essais ABTECT-UC et ENHANCE-CD, et l'avancement de son portefeuille de candidats médicaments Abivax Maladies Inflammatoires Chroniques Rectocolite Hémorragique Essais Cliniques Perspectives 2026
PRESS RELEASE published on 01/07/2026 at 22:05, 9 months 30 days ago Abivax Provides 2026 Corporate Outlook Abivax provides 2026 corporate outlook, highlighting market insights, trial progress, and pipeline advancements in treating chronic inflammatory diseases like UC and CD Abivax Chronic Inflammatory Diseases 2026 Corporate Outlook UC CD
Published on 11/06/2026 at 22:15, 19 hours 47 minutes ago Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
Published on 11/06/2026 at 13:00, 1 day 5 hours ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 1 day 5 hours ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 1 day 5 hours ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/07/2026 at 13:35, 4 hours 27 minutes ago Eurobattery Minerals board member and CEO remanded in custody in Sweden
Published on 11/06/2026 at 20:15, 21 hours 47 minutes ago African Medicines Agency Marks First Year of Operations with New Platforms to Strengthen Regulation and Support Manufacturing
Published on 11/06/2026 at 20:15, 21 hours 47 minutes ago L’Agence africaine des médicaments marque sa première année d’activité avec le lancement de nouvelles plateformes pour renforcer la réglementation et soutenir la fabrication
Published on 11/06/2026 at 19:15, 22 hours 47 minutes ago EQS-Adhoc: ABO Energy GmbH & Co. KGaA suspends the interest payment on the bond 2024/2029 due on 8 November 2026.
Published on 11/06/2026 at 19:00, 23 hours 2 minutes ago Finexity AG: FINEXITY issues 2026/2030 bond with a minimum of 7.00% p.a. – either conventionally in a securities account or as a crypto security in a wallet
Published on 11/06/2026 at 19:06, 22 hours 55 minutes ago ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES OCTOBRE 2026
Published on 11/06/2026 at 19:04, 22 hours 58 minutes ago ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 11/06/2026 at 19:01, 23 hours ago ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES OCTOBRE 2026
Published on 11/06/2026 at 19:00, 23 hours 2 minutes ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
